

PHARMACEUTICAL 2022

Stoke Therapeutics Inc. Rank 114 of 466







RealRate

PHARMACEUTICAL 2022

Stoke Therapeutics Inc. Rank 114 of 466

The relative strengths and weaknesses of Stoke Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Stoke Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Stoke Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 144% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	229,218
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,139
Liabilities, Non-Current	3,949
Other Assets	5,508
Other Compr. Net Income	-168
Other Expenses	0
Other Liabilities	0
Other Net Income	260
Other Revenues	0
Property and Equipment	4,139
Research and Development	54,168
Selling, General and Administrative Expense	31,897

Output Variable	Value in 1000 USD
Assets	238,865
Liabilities	21,088
Expenses	86,065
Revenues	0
Stockholders Equity	217,777
Net Income	-85,805
Comprehensive Net Income	-85,889
Economic Capital Ratio	222%

